Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2017

01-07-2017 | Original Article

Antiphospholipid antibodies proposed in the diagnosis of infective endocarditis

Authors: C. Zaratzian, F. Gouriet, H. Tissot-Dupont, J.-P. Casalta, M. Million, N. Bardin, D. Grisoli, G. Habib, D. Raoult

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2017

Login to get access

Abstract

Antiphospholipid antibodies (aPL) may occur alone or associated with other diseases. To evaluate aPL, tested as anticardiolipin antibodies (IgG aCL) in infective endocarditis (IE) diagnosis, we investigated their prevalence in a cohort of 651 patients with IE suspicion. aPL was significantly associated with definite IE versus IE-rejected patients. Their mean levels were significantly higher in patients with definite IE versus possible IE. When applied as Duke minor criterion, they were significantly more often positive, and at higher levels, in patients with definite IE than in patients with possible or rejected IE. aPL could be helpful in difficult cases of IE diagnosis.
Literature
1.
Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368(11):1033–1044CrossRefPubMed
2.
Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019–1027CrossRefPubMed
3.
Pardos-Gea J, Avegliano G, Evangelista A, Vilardell M, Ordi-Ros J (2013) Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study. Int J Rheum Dis 18(1):76–83CrossRefPubMed
4.
Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E (2010) Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg 5:101CrossRefPubMedPubMedCentral
5.
Greaves M, Cohen H, Machin SJ, Mackie I (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109(4):704–715CrossRefPubMed
6.
Million M, Walter G, Bardin N et al (2013) Immunoglobulin G anticardiolipin antibodies and progression to Q fever endocarditis. Clin Infect Dis 57(1):57–64CrossRefPubMed
7.
Contractor T, Bell A, Khasnis A, Silverberg BJ, Martinez MW (2013) Antiphospholipid antibody-associated non-infective mitral valve endocarditis successfully treated with medical therapy. J Heart Valve Dis 22(1):36–38PubMed
8.
Raoult D, Casalta JP, Richet H et al (2005) Contribution of systematic serological testing in diagnosis of infective endocarditis. J Clin Microbiol 43(10):5238–5242CrossRefPubMedPubMedCentral
9.
Fournier PE, Thuny F, Richet H et al (2010) Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clin Infect Dis 51(2):131–140CrossRefPubMed
10.
Verrot D, San-Marco M, Dravet C et al (1997) Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 103(1):33–37CrossRefPubMed
11.
Mahr A, Batteux F, Tubiana S et al (2014) Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol 66(6):1672–1677CrossRefPubMed
12.
Zuily S, Regnault V, Selton-Suty C et al (2011) Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 124(2):215–224CrossRefPubMed
13.
Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D (2014) Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J 16(3):162–167PubMed
14.
Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H (1999) The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol 33(5):1365–1371CrossRefPubMed
15.
Bojalil R, Mazón-González B, Carrillo-Córdova JR, Springall R, Amezcua-Guerra LM (2012) Frequency and clinical significance of a variety of autoantibodies in patients with definite infective endocarditis. J Clin Rheumatol 18(2):67–70CrossRefPubMed
16.
Ying CM, Yao DT, Ding HH, Yang CD (2014) Infective endocarditis with antineutrophil cytoplasmic antibody: report of 13 cases and literature review. PLoS One 9(2):e89777CrossRefPubMedPubMedCentral
17.
Aslangul E, Goulvestre C, Mallat Z, Mainardi JL (2014) Human bartonella infective endocarditis is associated with high frequency of antiproteinase 3 antibodies. J Rheumatol 41(2):408–410CrossRefPubMed
Metadata
Title
Antiphospholipid antibodies proposed in the diagnosis of infective endocarditis
Authors
C. Zaratzian
F. Gouriet
H. Tissot-Dupont
J.-P. Casalta
M. Million
N. Bardin
D. Grisoli
G. Habib
D. Raoult
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-2903-1

Other articles of this Issue 7/2017

European Journal of Clinical Microbiology & Infectious Diseases 7/2017 Go to the issue

Original Article

Evaluation of antimicrobial persistent activity of alcohol-based hand antiseptics against bacterial contamination

Erratum

Erratum to: Evaluating next-generation sequencing for direct clinical diagnostics in diarrhoeal disease

Original Article

Does active hepatitis C virus infection increase the risk for infection due to Staphylococcus aureus?

Original Article

Infections in intensive care unit adult patients harboring multidrug-resistant Pseudomonas aeruginosa: implications for prevention and therapy

Original Article

Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology

Original Article

Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits